Actively Recruiting
The Theranostic Value of STARD3 in Colorectal Cancer: The STAR Study
Led by Centro di Riferimento Oncologico - Aviano · Updated on 2023-11-18
150
Participants Needed
1
Research Sites
501 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims at verifying the overexpression of STARD3 in both early and advanced CRC patients derived tissues, to identify the pathways underpinning tumorigenesis and cancer progression in which STARD3 is involved. Moreover its role as a dynamic biomarker of treatment response and its part in treatment sensitivity will be explored.
CONDITIONS
Official Title
The Theranostic Value of STARD3 in Colorectal Cancer: The STAR Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed diagnosis of colorectal cancer, independently from diagnosis stage.
- Age 518 years.
- Signed informed consent form.
- Availability of tissue and blood samples stored at the Institutional Biobank for research purposes.
You will not qualify if you...
- Patients for which the tumour biobanking process could compromise the diagnostic assessments.
- Pregnancy or breast-feeding.
- History of concomitant or previous malignancy in the previous 5 years, except for adequately treated cutaneous squamous cell carcinoma or surgically removed in situ cervical carcinoma.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Centro di Riferimento Oncologico (CRO) di Aviano - IRCCS
Aviano, Pordenone, Italy, 33081
Actively Recruiting
Research Team
V
Vincenzo Canzonieri, MD, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here